British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, UK.
Trials. 2023 Aug 10;24(1):512. doi: 10.1186/s13063-023-07473-z.
Vasovagal reactions (VVRs) are the most common acute complications of blood donation. Responsible for substantial morbidity, they also reduce the likelihood of repeated donations and are disruptive and costly for blood services. Although blood establishments worldwide have adopted different strategies to prevent VVRs (including water loading and applied muscle tension [AMT]), robust evidence is limited. The Strategies to Improve Donor Experiences (STRIDES) trial aims to reliably assess the impact of four different interventions to prevent VVRs among blood donors.
STRIDES is a cluster-randomised cross-over/stepped-wedge factorial trial of four interventions to reduce VVRs involving about 1.4 million whole blood donors enrolled from all 73 blood donation sites (mobile teams and donor centres) of National Health Service Blood and Transplant (NHSBT) in England. Each site ("cluster") has been randomly allocated to receive one or more interventions during a 36-month period, using principles of cross-over, stepped-wedge and factorial trial design to assign the sequence of interventions. Each of the four interventions is compared to NHSBT's current practices: (i) 500-ml isotonic drink before donation (vs current 500-ml plain water); (ii) 3-min rest on donation chair after donation (vs current 2 min); (iii) new modified AMT (vs current practice of AMT); and (iv) psychosocial intervention using preparatory materials (vs current practice of nothing). The primary outcome is the number of in-session VVRs with loss of consciousness (i.e. episodes involving loss of consciousness of any duration, with or without additional complications). Secondary outcomes include all in-session VVRs (i.e. with and without loss of consciousness), all delayed VVRs (i.e. those occurring after leaving the venue) and any in-session non-VVR adverse events or reactions.
The STRIDES trial should yield novel information about interventions, singly and in combination, for the prevention of VVRs, with the aim of generating policy-shaping evidence to help inform blood services to improve donor health, donor experience, and service efficiency.
ISRCTN: 10412338. Registration date: October 24, 2019.
血管迷走性反应(VVRs)是献血最常见的急性并发症。它们导致了大量的发病率,降低了重复献血的可能性,并且对血液服务造成了干扰和成本。尽管世界范围内的血液机构已经采用了不同的策略来预防 VVRs(包括水负荷和应用肌肉张力[AMT]),但强有力的证据仍然有限。“改善献血者体验策略”(STRIDES)试验旨在可靠地评估四种不同干预措施预防献血者 VVRs 的影响。
STRIDES 是一项针对预防 VVRs 的四项干预措施的集群随机交叉/逐步楔形因子试验,涉及英格兰国民保健署(NHSBT)所有 73 个献血地点(流动团队和献血中心)招募的约 140 万全血献血者。每个地点(“集群”)在 36 个月的时间内随机分配接受一项或多项干预措施,采用交叉、逐步楔形和因子试验设计的原则来分配干预措施的顺序。四项干预措施中的每一项都与 NHSBT 的现行做法进行比较:(i)献血前 500 毫升等渗饮料(与目前的 500 毫升普通水相比);(ii)献血后在献血椅上休息 3 分钟(与目前的 2 分钟相比);(iii)新的改良 AMT(与目前的 AMT 实践相比);(iv)使用预备材料的心理社会干预(与目前的什么都不做相比)。主要结局是在会话期间发生的伴有意识丧失的 VVR 数量(即意识丧失持续时间不论长短的发作,伴有或不伴有其他并发症)。次要结局包括所有会话期间的 VVR(即伴有或不伴有意识丧失)、所有延迟的 VVR(即离开场地后发生的那些)以及任何会话期间的非 VVR 不良事件或反应。
STRIDES 试验应该产生关于干预措施的新信息,单独和联合使用,以预防 VVRs,旨在产生影响政策制定的证据,以帮助为血液服务提供信息,以改善献血者的健康、献血者的体验和服务效率。
ISRCTN:10412338。注册日期:2019 年 10 月 24 日。